Posaconazole for the prophylaxis of invasive aspergillosis in acute myeloid leukemia: Is it still useful outside the clinical trial setting?

Therapeutic Advances in Hematology
Tsung-Chih ChenChieh-Lin Jerry Teng

Abstract

Posaconazole prophylaxis during remission induction chemotherapy not only decreases the incidence of invasive aspergillosis (IA) but also improves the overall survival rate among patients with acute myeloid leukemia (AML). However, it remains debatable whether this result applies to patients in a real-world setting. We retrospectively assessed 208 adult patients with newly diagnosed AML who underwent remission induction therapy. These 208 patients were stratified into the posaconazole prophylaxis group (n = 58) and no antifungal prophylaxis group (n = 150). Multivariate analyses showed that induction failure significantly increased the risk of proven or probable IA during the first induction chemotherapy [hazard ratio (HR), 10.47; 95% confidence interval (CI), 1.73-63.45; p = 0.011] and the entire course of AML treatment (HR, 4.48; 95% CI, 1.71-11.75; p = 0.002). However, posaconazole prophylaxis did not reduce the risk of IA during the first induction chemotherapy (HR, 1.47; 95% CI, 0.14-15.04; p = 0.746) and during the entire course of AML treatment (HR, 1.09; 95% CI, 0.29-4.09; p = 0.896). Furthermore, there was no significant difference in overall survival between these two groups of patients (514 versus 689 days; p = 0.454...Continue Reading

References

Jan 26, 2007·The New England Journal of Medicine·Oliver A CornelyDavid Angulo-Gonzalez
May 9, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Ben De PauwUNKNOWN National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
May 1, 2009·The New England Journal of Medicine·Brahm H Segal
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan BurnettBob Löwenberg
Jun 12, 2013·Clinica Chimica Acta; International Journal of Clinical Chemistry·Yosuke SuzukiJun-ichi Kadota
May 8, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Jose F Camargo, Shahid Husain
Jul 2, 2016·Blood Cancer Journal·I De Kouchkovsky, M Abdul-Hay
Aug 3, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Thomas F PattersonJohn E Bennett
Oct 28, 2016·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kuang-Hsi ChangChieh-Lin Jerry Teng
Mar 31, 2019·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Emilia HardakIlana Oren
Jul 30, 2019·European Journal of Haematology·Yu-Chiao ChiuChieh-Lin Jerry Teng

❮ Previous
Next ❯

Methods Mentioned

BETA
bronchoalveolar lavage

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Aspergillosis

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.

Aspergillosis (ASM)

Aspergillosis is the name given to a wide variety of diseases caused by infection by fungi of the genus Aspergillus. Aspergillosis occurs in chronic or acute forms which are clinically very distinct. Most cases of acute aspergillosis occur in patients with severely compromised immune systems. Chronic colonization or infection can cause complications in people with underlying respiratory illnesses. Discover the latest research on aspergillosis here.